Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2 ~ February 3, 2023

_________________________________________________________________________________________________________

Editor’s Note: Please observe the authors of this article without exception seeming to be Chinese. I do not doubt the efficacy for this article, yet perhaps another reason prompts the destruction of chickens/eggs. Recent changes made to chicken feed seem to be making the egg yokes less nutritious/healthy, so perhaps “tainted” chickens/eggs have been removed as a protective measure for human health. By this measure, the safety of our food supply has been maintained, leaving us to BE in…

Quantum Joy!

________________________________________________________________________________________________________

Shuangshi Wei  ¹ , Shengbao Duan  ² , Xiaomei Liu  ¹ , Hongmei Wang  ¹ , Shaohua Ding  ¹ , Yezhou Chen  ¹ , Jinsong Xie  ¹ , Jingjing Tian  ¹ , Nong Yu  ³ , Pingju Ge  ⁴ , Xinglin Zhang  ⁴ , Xiaohong Chen  ⁴ , Yong Li  ⁵ , Qinglin Meng  ⁶

Affiliations

• PMID: 33191178
• PMCID: PMC7608017
• DOI: 10.1016/j.intimp.2020.107172

Free PMC article

Abstract

The SARS-CoV-2 virus is still spreading worldwide, and there is an urgent need to effectively prevent and control this pandemic. This study evaluated the potential efficacy of Egg Yolk Antibodies (IgY) as a neutralizing agent against the SARS-CoV-2. We investigated the neutralizing effect of anti-spike-S1 IgYs on the SARS-CoV-2 pseudovirus, as well as its inhibitory effect on the binding of the coronavirus spike protein mutants to human ACE2. Our results show that the anti-Spike-S1 IgYs showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro. It might be a feasible tool for the prevention and control of ongoing COVID-19.

Keywords: Chicken Egg Yolk Antibodies; IgY; Neutralizing agent; SARS-CoV-2; Spike protein variants.

Copyright © 2020 Elsevier B.V. All rights reserved.

Similar articles

• Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction. Eka Saputri M, Aisyah Rahmalia Effendi S, Nadila R, Azzam Fajar S, Damajanti Soejoedono R, Handharyani E, Nadia Poetri O.Int Immunopharmacol. 2022 Nov;112:109280. doi: 10.1016/j.intimp.2022.109280. Epub 2022 Sep 28.PMID: 36183680Free PMC article.
• Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2. Shu CJ, Huang X, Tang HH, Mo DD, Zhou JW, Deng C.Zool Res. 2021 Mar 18;42(2):170-181. doi: 10.24272/j.issn.2095-8137.2020.301.PMID: 33738989Free PMC article.
• Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. Passariello M, Gentile C, Ferrucci V, Sasso E, Vetrei C, Fusco G, Viscardi M, Brandi S, Cerino P, Zambrano N, Zollo M, De Lorenzo C.Sci Rep. 2021 May 26;11(1):11046. doi: 10.1038/s41598-021-90348-7.PMID: 34040046Free PMC article.
• Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker. Bao L, Zhang C, Lyu J, Yi P, Shen X, Tang B, Zhao H, Ren B, Kuang Y, Zhou L, Li Y.J Appl Microbiol. 2022 Mar;132(3):2421-2430. doi: 10.1111/jam.15340. Epub 2021 Nov 3.PMID: 34706134Free PMC article.
• Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines. Li J, Wang P, Tracey KJ, Wang H.Mol Med. 2021 May 22;27(1):49. doi: 10.1186/s10020-021-00313-3.PMID: 34022793Free PMC article.

See all similar articles

Cited by

• SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice. El-Kafrawy SA, Odle A, Abbas AT, Hassan AM, Abdel-Dayem UA, Qureshi AK, Wong LR, Zheng J, Meyerholz DK, Perlman S, Zumla A, Azhar EI.PLoS Pathog. 2022 Sep 19;18(9):e1010782. doi: 10.1371/journal.ppat.1010782. eCollection 2022 Sep.PMID: 36121829Free PMC article.
• Development of a Monoclonal scFv against Cytotoxin to Neutralize Cytolytic Activity Induced by Naja atra Venom on Myoblast C2C12 Cells. Liu CC, Wu CJ, Chou TY, Liaw GW, Hsiao YC, Chu LJ, Lee CH, Wang PJ, Hsieh CH, Chen CK, Yu JS.Toxins (Basel). 2022 Jul 4;14(7):459. doi: 10.3390/toxins14070459.PMID: 35878197Free PMC article.
• Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review. Azali MA, Mohamed S, Harun A, Hussain FA, Shamsuddin S, Johan MF.J Genet Eng Biotechnol. 2022 Jul 6;20(1):98. doi: 10.1186/s43141-022-00368-7.PMID: 35792966Free PMC article.Review.
• A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa. Rahbar MR, Mubarak SMH, Hessami A, Khalesi B, Pourzardosht N, Khalili S, Zanoos KA, Jahangiri A.Sci Rep. 2022 Jun 27;12(1):10852. doi: 10.1038/s41598-022-14877-5.PMID: 35760825Free PMC article.
• Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19. Frumkin LR, Lucas M, Scribner CL, Ortega-Heinly N, Rogers J, Yin G, Hallam TJ, Yam A, Bedard K, Begley R, Cohen CA, Badger CV, Abbasi SA, Dye JM, McMillan B, Wallach M, Bricker TL, Joshi A, Boon ACM, Pokhrel S, Kraemer BR, Lee L, Kargotich S, Agochiya M, John TS, Mochly-Rosen D.Front Immunol. 2022 Jun 1;13:899617. doi: 10.3389/fimmu.2022.899617. eCollection 2022.PMID: 35720389Free PMC article.Clinical Trial.

See all “Cited by” articles

References

1. Zhou P., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. – PMC – PubMed